BR0315645A - Polipetìdeos de fusão de actrib e seus usos - Google Patents
Polipetìdeos de fusão de actrib e seus usosInfo
- Publication number
- BR0315645A BR0315645A BR0315645-1A BR0315645A BR0315645A BR 0315645 A BR0315645 A BR 0315645A BR 0315645 A BR0315645 A BR 0315645A BR 0315645 A BR0315645 A BR 0315645A
- Authority
- BR
- Brazil
- Prior art keywords
- actrib
- fusion polypeptides
- methods
- gdf
- diagnosing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
Abstract
"POLIPEPTìDEOS DE FUSãO DE ACTRIIB E SEUS USOS". A presente invenção refere-se a métodos e composições para inibir a atividade do fator -8 de crescimento e diferenciação (GDF-8) in vitro e in vivo. Os métodos e composições podem ser usados para diagnosticar, prevenir ou tratar distúrbios degenerativos do músculo, osso ou da homeostasia de glicose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42104102P | 2002-10-25 | 2002-10-25 | |
PCT/US2003/031516 WO2004039948A2 (en) | 2002-10-25 | 2003-10-24 | Actriib fusion polypeptides and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315645A true BR0315645A (pt) | 2005-08-30 |
Family
ID=32230212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315645-1A BR0315645A (pt) | 2002-10-25 | 2003-10-24 | Polipetìdeos de fusão de actrib e seus usos |
Country Status (11)
Country | Link |
---|---|
US (5) | US20040223966A1 (pt) |
EP (1) | EP1572961B1 (pt) |
JP (2) | JP4685452B2 (pt) |
AT (1) | ATE448686T1 (pt) |
AU (1) | AU2003279817A1 (pt) |
BR (1) | BR0315645A (pt) |
CA (1) | CA2501180A1 (pt) |
DE (1) | DE60330181D1 (pt) |
ES (1) | ES2337890T3 (pt) |
MX (1) | MXPA05004224A (pt) |
WO (1) | WO2004039948A2 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
WO2003072714A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
JP4429729B2 (ja) * | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | Gasp1;フォリスタチンドメイン含有タンパク質 |
US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
US20040138118A1 (en) * | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
EP1635870A2 (en) * | 2003-06-02 | 2006-03-22 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Alk7およびミオスタチン阻害剤ならびにその使用 |
AU2012244215B2 (en) * | 2004-07-23 | 2014-11-27 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
AU2015200950B2 (en) * | 2004-07-23 | 2017-04-27 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
DK2332977T3 (en) * | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
BRPI0514253A (pt) * | 2004-08-12 | 2008-06-03 | Wyeth Corp | terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8 |
TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
JP2008537488A (ja) * | 2005-03-23 | 2008-09-18 | ワイス | Gdf−8モジュレート物質の検出 |
CA2601086A1 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
CN103450359B (zh) | 2005-08-19 | 2018-07-24 | 惠氏有限责任公司 | 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途 |
US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
AU2011237541B2 (en) * | 2005-11-01 | 2014-05-15 | Amgen Inc. | Novel activin receptor and uses thereof |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CA3045808C (en) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for promoting bone growth |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
AU2016250354B2 (en) * | 2006-12-18 | 2019-01-17 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
AU2013221910B2 (en) * | 2006-12-18 | 2016-11-17 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
ES2415666T3 (es) * | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama |
TW201907946A (zh) * | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
AU2013203266B2 (en) * | 2007-02-02 | 2016-04-28 | Acceleron Pharma Inc. | Variants derived from ActRIIB and uses therefor |
EP2484372A1 (en) * | 2007-02-09 | 2012-08-08 | Acceleron Pharma, Inc. | Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients |
TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
LT2170396T (lt) | 2007-08-03 | 2017-03-10 | Summit (Oxford) Limited | Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
CA2699936A1 (en) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009158025A2 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
HRP20230761T1 (hr) | 2008-08-14 | 2023-10-13 | Acceleron Pharma Inc. | Gdf zamke |
EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
US8138142B2 (en) * | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
AU2010258931B2 (en) * | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
US8293881B2 (en) | 2009-06-12 | 2012-10-23 | Acceleron Pharma Inc. | Isolated nucleic acid encoding a truncated ActRIIB fusion protein |
CN102781518A (zh) * | 2009-09-09 | 2012-11-14 | 阿塞勒隆制药公司 | Actriib拮抗剂及其给药和用途 |
WO2011056896A1 (en) * | 2009-11-03 | 2011-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
US20110268736A1 (en) * | 2010-04-30 | 2011-11-03 | Children's Medical Center Corporation | Method for treating congenital myopathy |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
EP2638065A4 (en) | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | ACTRIIA BINDING AGENTS AND USES THEREOF |
ES2641877T3 (es) * | 2011-05-06 | 2017-11-14 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Inmunotoxina recombinante dirigida a mesotelina |
KR20170021919A (ko) | 2011-10-21 | 2017-02-28 | 화이자 인코포레이티드 | 철을 첨가하여 세포 배양을 개선하는 방법 |
SG10201605027XA (en) | 2011-12-19 | 2016-08-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
RS60318B1 (sr) | 2012-08-01 | 2020-07-31 | Ikaika Therapeutics Llc | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela |
JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
WO2014071158A1 (en) | 2012-11-02 | 2014-05-08 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
EP3816625A1 (en) | 2013-05-06 | 2021-05-05 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
CA2951926C (en) | 2014-06-13 | 2023-01-10 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
ES2863564T3 (es) | 2015-04-06 | 2021-10-11 | Acceleron Pharma Inc | Heteromultímeros ALK7:ActRIIB y usos de los mismos |
SG11201708351XA (en) | 2015-04-22 | 2017-11-29 | Alivegen Usa Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
WO2018067879A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
GB201620119D0 (en) | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
WO2019094751A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
JP2021518745A (ja) | 2018-01-12 | 2021-08-05 | ケロス セラピューティクス インコーポレイテッドKeros Therapeutics,Inc. | アクチビンiib型受容体変異体およびそれらの使用方法 |
AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
JP2807287B2 (ja) * | 1989-10-13 | 1998-10-08 | 株式会社医学生物学研究所 | ペプチドおよびその用途 |
US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
EP1333035A3 (en) * | 1993-03-19 | 2004-07-07 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
CA2161808C (en) * | 1993-05-12 | 2008-08-05 | Anthony J. Celeste | Bmp-11 compositions |
US5831050A (en) * | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
PT716610E (pt) * | 1993-08-26 | 2006-08-31 | Genetics Inst Llc | Proteinas morfogeneticas dos ossos de seres humanos para utilizacao em regeneracao neural |
US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
ES2251721T3 (es) * | 1994-07-08 | 2006-05-01 | The Johns Hopkins University School Of Medicine | Factor-11 de diferenciacion del crecimiento. |
US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6121415A (en) * | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
EP1075272B1 (en) * | 1998-05-06 | 2009-07-15 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
JP4429729B2 (ja) * | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | Gasp1;フォリスタチンドメイン含有タンパク質 |
WO2003072714A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
US20040138118A1 (en) * | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
ATE496938T1 (de) * | 2002-12-20 | 2011-02-15 | Amgen Inc | Myostatin hemmende bindungsstoffe |
WO2005028517A2 (en) * | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
EP1635870A2 (en) * | 2003-06-02 | 2006-03-22 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
US20050157125A1 (en) * | 2004-01-21 | 2005-07-21 | Silverbrook Research Pty Ltd | Inkjet printer cartridge with integral shield |
CA2601086A1 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
JP2008537488A (ja) * | 2005-03-23 | 2008-09-18 | ワイス | Gdf−8モジュレート物質の検出 |
-
2003
- 2003-10-22 US US10/689,677 patent/US20040223966A1/en not_active Abandoned
- 2003-10-24 CA CA002501180A patent/CA2501180A1/en not_active Abandoned
- 2003-10-24 AT AT03773145T patent/ATE448686T1/de not_active IP Right Cessation
- 2003-10-24 BR BR0315645-1A patent/BR0315645A/pt not_active IP Right Cessation
- 2003-10-24 MX MXPA05004224A patent/MXPA05004224A/es active IP Right Grant
- 2003-10-24 EP EP03773145A patent/EP1572961B1/en not_active Expired - Lifetime
- 2003-10-24 JP JP2004548352A patent/JP4685452B2/ja not_active Expired - Fee Related
- 2003-10-24 ES ES03773145T patent/ES2337890T3/es not_active Expired - Lifetime
- 2003-10-24 WO PCT/US2003/031516 patent/WO2004039948A2/en active Search and Examination
- 2003-10-24 AU AU2003279817A patent/AU2003279817A1/en not_active Abandoned
- 2003-10-24 DE DE60330181T patent/DE60330181D1/de not_active Expired - Lifetime
-
2007
- 2007-08-07 US US11/835,215 patent/US20090087433A1/en not_active Abandoned
- 2007-08-07 US US11/835,145 patent/US20090087375A1/en not_active Abandoned
- 2007-08-07 US US11/835,248 patent/US20080089897A1/en not_active Abandoned
-
2010
- 2010-01-28 JP JP2010017449A patent/JP2010138179A/ja not_active Withdrawn
- 2010-12-10 US US12/965,219 patent/US20110250198A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004039948A2 (en) | 2004-05-13 |
JP2010138179A (ja) | 2010-06-24 |
US20110250198A1 (en) | 2011-10-13 |
WO2004039948A3 (en) | 2006-07-27 |
ES2337890T3 (es) | 2010-04-30 |
AU2003279817A1 (en) | 2004-05-25 |
DE60330181D1 (de) | 2009-12-31 |
EP1572961B1 (en) | 2009-11-18 |
EP1572961A2 (en) | 2005-09-14 |
JP2006516886A (ja) | 2006-07-13 |
US20080089897A1 (en) | 2008-04-17 |
US20090087433A1 (en) | 2009-04-02 |
MXPA05004224A (es) | 2005-09-20 |
ATE448686T1 (de) | 2009-12-15 |
EP1572961A4 (en) | 2007-05-23 |
CA2501180A1 (en) | 2004-05-13 |
JP4685452B2 (ja) | 2011-05-18 |
US20040223966A1 (en) | 2004-11-11 |
US20090087375A1 (en) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315645A (pt) | Polipetìdeos de fusão de actrib e seus usos | |
WO2003029418A3 (en) | Proliferation and differentiation of stem cells using extracellular matrix and other molecules | |
MXPA04001334A (es) | Materiales y metodos para promover la reparacion de tejido nervioso. | |
IS7770A (is) | Hlutleysandi mótefni gegn GDF-8 og notkun theirra | |
WO2003027248A8 (en) | Antibody inhibitors of gdf-8 and uses thereof | |
TW200510306A (en) | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
BR0014078A (pt) | Inibidores de fator xa | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
TW200616632A (en) | Compounds modulating c-kit activity and uses therefor | |
HK1082435A1 (en) | Compositions and methods for coating medical implants | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
WO2000071507A3 (en) | INHIBITORS OF FACTOR Xa | |
NO20012774D0 (no) | Preparat og metode hvor det gjöres bruk av eteriske planteoljer | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
HK1077193A1 (en) | Alpha-7 nicotinic receptor agonists and statins incombination | |
WO2003094617A3 (en) | Use of vegf for treating bone defects | |
WO2004039248A3 (en) | Repairing or replacing tissues or organs | |
BR0317888A (pt) | Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos | |
BRPI0414215A (pt) | tienopirazóis | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
DE60102147D1 (de) | Anti-gefrier proteine, deren herstellung und verwendung | |
WO2005000403A3 (en) | Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |